Refractory Primary Malignant Central Nervous System Neoplasm
4 clinical trials · Condition
◉ Watch Refractory Primary Malignant Central Nervous System Neoplasm
| Record | Firm | Date |
|---|---|---|
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (NCT04870944) | Children's Oncology Group | 2022-01-28 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994) | National Cancer Institute (NCI) | 2018-11-14 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592) | National Cancer Institute (NCI) | 2017-05-18 |
Track Refractory Primary Malignant Central Nervous System Neoplasm automatically
Every clearance here is in the API, with alerts when new ones post.